The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|July 31, 2017
Deadline Looms for Applications to Host EMA
Author(s)Philip Ward
Advertisement
European Union countries have until midnight on July 31 to enter the bidding contest to provide a new home for European Medicines Agency (EMA). About 20 applications are expected, according to
The European Banking Authority and the EMA, both based in Canary Wharf in London, employ just over 1,000 staff between them, and the agencies will be relocated from the UK after Brexit.
“There will be fierce competition to attract the agencies’ highly skilled employees, their families and the business that comes with them. This includes 40,000 hotel stays for visitors each year,” the BBC article noted. “Countries have printed glossy brochures, posted promotional videos online and hired lobbying firms.”
The European Commission will assess the entries based on the quality of office space, job opportunities for spouses, and transport links, and European ministers will use a complicated voting system to choose the winners in November, the report added.
Philip Ward is the European Editor for Applied Clinical Trials.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Syneos Health, Optum Partner on Adaptive Clinical Development Model
4
ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit
5